Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668109 | 0.92 | CA2 (0.37) | CA2ARG1 | |
| SCHEMBL221780 | 0.83 | ARG1 (0.33) | CA2ARG1 | |
| SCHEMBL7205373 | 0.81 | ARG1 (0.32) | CA2ARG1 | |
| SCHEMBL9953134 | 0.80 | CA2 (0.44) | CA2ARG1 | |
| SCHEMBL8315940 | 0.77 | ARG1 (0.32) | CA2ARG1 | |
| SCHEMBL1908883 | 0.76 | ALDH1A1 (0.37) | — | |
| SCHEMBL8814117 | 0.76 | — | — | |
| SCHEMBL12384260 | 0.74 | — | — | |
| SCHEMBL12424218 | 0.74 | CA2 (0.33) | CA2 | |
| SCHEMBL7206090 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
| US-6610518-B2 | Using Cytochrome p450 | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020012977-A1 | Enzymatic oxidations | PFIZER PRODUCTS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-1160331-A1 | Enzymatic oxidations | Pfizer Limited (GB) | 2001-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | CA2 3053/4885ARG1 16/4885 |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | AAK1, ADCK1, NCK1 | CA2 4102/4885ARG1 3836/4885 |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | CA2 940/4885ARG1 563/4885 |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | PIK3R5, PIK3CA, PIK3R1 | CA2 3404/4885ARG1 1860/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | CA2 940/4885ARG1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.